RARE · Insider Trading

Ultragenyx Pharmaceutical Inc.

Every open-market purchase and sale reported by RARE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
22
code S
Reporting Insiders
16
current holders
RARE — Recent Form 4 Transactions (latest 2026-10-19)
FiledInsiderRole TypeSharesValue
2026-10-19 Howard Horn Chief Financial Officer Sell −7,066 −$107.90K
2026-09-15 Theodore Alan Huizenga SVP, Chief Accounting Officer Sell −1,283 −$17.41K
2026-09-08 Theodore Alan Huizenga SVP, Chief Accounting Officer Sell −161 −$2.25K
2026-08-04 Karah Herdman Parschauer EVP and Chief Legal Officer Sell −1,900 −$47.35K
2026-08-04 Howard Horn Chief Financial Officer Sell −4,696 −$117.02K
2026-07-06 Howard Horn Chief Financial Officer Sell −4,698 −$155.64K
2026-06-15 Corazon (Corsee) D. Sanders Director Sell −2,000 −$50.10K
2026-06-15 Karah Herdman Parschauer EVP and Chief Legal Officer Sell −1,899 −$46.75K
2026-06-01 Howard Horn Chief Financial Officer Sell −4,653 −$110.60K
2026-05-18 Deborah Dunsire Director A +7,751 —
2026-05-18 Daniel G Welch Director A +7,751 —
2026-05-18 Michael Narachi Director A +7,751 —
2026-05-18 Matthew K Fust Director A +7,751 —
2026-05-18 Corazon (Corsee) D. Sanders Director A +7,751 —
2026-05-18 Amrit Ray Director A +7,751 —
2026-05-18 Shehnaaz Suliman Director MIXED +2,011 −$144.19K
2026-05-06 Eric Crombez EVP and Chief Medical Officer Sell −344 −$8.59K
2026-05-04 Howard Horn Chief Financial Officer Sell −4,683 −$116.61K
2026-04-24 Theodore Alan Huizenga SVP, Chief Accounting Officer A +20,241 —
2026-04-20 Howard Horn Chief Financial Officer A +34,674 —
2026-04-20 Eric Crombez EVP and Chief Medical Officer A +34,674 —
2026-04-20 Erik Harris EVP & Chief Commercial Officer A +28,895 —
2026-04-20 Karah Herdman Parschauer EVP and Chief Legal Officer A +28,895 —
2026-04-20 John Richard Pinion See Remarks A +23,116 —
2026-04-20 Dennis Karl Huang See Remarks A +23,116 —
2026-04-20 Emil D Kakkis President & CEO A +76,745 —
2026-04-02 Howard Horn Chief Financial Officer Sell −4,683 −$98.20K
2026-03-10 Karah Herdman Parschauer EVP and Chief Legal Officer Sell −9,526 −$208.31K
2026-03-03 Dennis Karl Huang See Remarks MIXED +10,138 −$23.37K
2026-03-03 Eric Crombez EVP and Chief Medical Officer MIXED +4,614 −$160.26K
2026-03-03 Howard Horn Chief Financial Officer MIXED −3,901 −$227.54K
2026-03-03 Theodore Alan Huizenga SVP, Chief Accounting Officer MIXED −1,780 −$40.67K
2026-03-03 Karah Herdman Parschauer EVP and Chief Legal Officer MIXED +3,002 −$185.48K
2026-03-03 Emil D Kakkis President & CEO MIXED +16,773 −$1.24M
2026-03-03 Erik Harris EVP & Chief Commercial Officer MIXED +1,104 −$240.29K
2026-03-03 John Richard Pinion See Remarks MIXED +1,108 −$228.66K
2026-02-03 Howard Horn Chief Financial Officer Sell −3,061 −$72.12K
2026-01-05 Howard Horn Chief Financial Officer Sell −3,150 −$71.95K
2025-12-30 Theodore Alan Huizenga SVP, Chief Accounting Officer Sell −85 −$2.92K
2025-12-11 Howard Horn Chief Financial Officer Sell −3,081 −$112.09K
2025-10-14 Howard Horn Chief Financial Officer Sell −7,942 −$250.25K
2025-09-19 Theodore Alan Huizenga SVP, Chief Accounting Officer Sell −64 −$1.87K
2025-09-12 Karah Herdman Parschauer EVP and Chief Legal Officer Sell −2,450 −$76.37K
2025-09-08 Theodore Alan Huizenga SVP, Chief Accounting Officer Sell −84 −$2.64K
2025-06-23 Corazon (Corsee) D. Sanders Director Sell −2,405 −$89.92K
2025-05-19 Amrit Ray Director A +5,740 —
2025-05-19 Deborah Dunsire Director A +5,740 —
2025-05-19 Matthew K Fust Director A +5,740 —
2025-05-19 Michael Narachi Director A +5,740 —
2025-05-19 Corazon (Corsee) D. Sanders Director A +5,740 —
RARE — Current Insider Holders
InsiderRole Shares HeldValue
Emil D Kakkis President & CEO 2,694,724 $46.24M
Thomas Richard Kassberg CBO & EVP 264,730 $4.54M
Dennis Karl Huang See Remarks 147,845 $2.54M
John Richard Pinion See Remarks 133,142 $2.28M
Erik Harris EVP & Chief Commercial Officer 118,410 $2.03M
Eric Crombez EVP and Chief Medical Officer 111,189 $1.91M
Karah Herdman Parschauer EVP and Chief Legal Officer 92,562 $1.59M
Howard Horn Chief Financial Officer 89,229 $1.53M
Theodore Alan Huizenga SVP, Chief Accounting Officer 67,863 $1.16M
Daniel G Welch Director 40,441 $693.97K
Michael Narachi Director 40,441 $693.97K
Deborah Dunsire Director 38,566 $661.79K
Matthew K Fust Director 33,696 $578.22K
Amrit Ray Director 31,116 $533.95K
Shehnaaz Suliman Director 27,951 $479.64K
Corazon (Corsee) D. Sanders Director 21,095 $361.99K
RARE Insider Trading FAQ
Who are the insiders at RARE?
16 officers, directors and 10%+ beneficial owners currently report holdings in RARE via SEC Form 4.
Are RARE insiders buying or selling?
Across the 50 most recent Form 4 filings for RARE, 0 were open-market purchases (code P) and 22 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is RARE insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent RARE filing is dated 2026-10-19.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the RARE quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.